Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants.

Publication date: Jun 14, 2024

Immunological memory to vaccination and viral infection involves coordinated action of B and T-cells, thus integrated analysis of these two components is critical for understanding their contributions to protection against breakthrough infections (BI). We investigated cellular and humoral immune responses to SARS-CoV-2 infection and/or COVID-19 vaccination in participants from the Avon Longitudinal Study of Parents and Children (ALSPAC). The magnitude of antibody and T-cell responses following the second vaccine dose was associated with protection against BI in participants with a history of SARS-CoV-2 infection (cases), but not in infection-naive controls. Youdens index thresholds for protection against BI were calculated for all immune measures. Anti-Spike IgG (>666.4 BAU/mL) and anti-nucleocapsid N pan Ig (>0.1332 BAU/mL) thresholds combined were 100% sensitive and 83% specific for cases without BI over 8-months follow-up. Collectively these results point to the superior protective effect of hybrid immunity and have implications for the design of next-generation COVID-19 vaccines.

PDF

Concepts Keywords
1000g Anti
June Bristol
Receptionists Cov
Vaccines Covid
Zombie Figure
Igg
Infection
Medrxiv
Participants
Preprint
Protection
Sars
Serum
Specific
Vaccination

Semantics

Type Source Name
disease VO rapid vaccination
disease IDO pathogen
disease VO population
disease VO vaccine
disease MESH infection
disease IDO history
disease VO vaccine dose
disease IDO cell
pathway REACTOME SARS-CoV-2 Infection
disease MESH viral infection
disease VO vaccination
disease MESH COVID-19
disease MESH breakthrough infection
disease VO vaccine effectiveness
disease IDO assay
disease IDO facility
disease MESH Infectious Diseases
disease IDO production
disease VO storage
drug DRUGBANK Nitrogen
drug DRUGBANK Ethanol
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Phosphate ion
drug DRUGBANK Flunarizine
drug DRUGBANK Edetic Acid
disease IDO blood
disease IDO object
disease VO time
disease VO viability
disease MESH lifestyle
disease IDO symptom
disease VO pregnant women
drug DRUGBANK Medical air
disease VO manufacturer
disease VO volume
drug DRUGBANK Streptomycin
drug DRUGBANK L-Glutamine
drug DRUGBANK Carbonate ion
disease VO ORF
drug DRUGBANK Amino acids
disease VO primary vaccination
disease VO vaccination dose
disease MESH Delta infection
disease MESH seroconversion
disease VO frequency
disease VO vaccination frequency
disease VO effective
drug DRUGBANK Isoxaflutole
drug DRUGBANK Saquinavir
disease VO effectiveness
disease IDO susceptibility
disease MESH re infection
disease VO dose
disease VO vaccinated

Download Document

(Visited 3 times, 1 visits today)